MABWELL (SHANGHAI) BIOSCIENCE CO., LTD. Financials Mabwell (Shanghai) Bioscience Co., Ltd.
Equities
688062
CNE100005RD2
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 33.6 CNY | +1.33% |
|
-3.97% | +2.78% |
| 07/05 | Mabwell Announces FDA Grants Orphan Drug Designation to 9MW2821 | CI |
| 29/04 | Mabwell Bioscience Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Capitalization 1 | 5,774 | 13,063 | 13,427 | - | - |
| Enterprise Value (EV) 1 | 5,774 | 13,063 | 13,427 | 13,427 | 13,427 |
| P/E ratio | -5.92 x | -12.4 x | -15 x | -21.6 x | -108 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | - | 102 x | 39.4 x | 12.4 x | 6.93 x |
| EV / Revenue | - | 102 x | 39.4 x | 12.4 x | 6.93 x |
| EV / EBITDA | - | -13.4 x | -16.8 x | -28.5 x | 153 x |
| EV / FCF | - | -10.2 x | -15.6 x | -21.4 x | 1,504 x |
| FCF Yield | - | -9.82% | -6.41% | -4.67% | 0.07% |
| Price to Book | - | 5.05 x | 7.94 x | 12.6 x | 14.9 x |
| Nbr of stocks (in thousands) | 3,99,600 | 3,99,600 | 3,99,600 | - | - |
| Reference price 2 | 14.45 | 32.69 | 33.60 | 33.60 | 33.60 |
| Announcement Date | 20/02/23 | 23/02/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | - | 127.7 | 340.8 | 1,086 | 1,939 |
| EBITDA 1 | - | -973 | -798 | -470.7 | 87.5 |
| EBIT 1 | - | -1,053 | -948 | -648.9 | -156.5 |
| Operating Margin | - | -824.53% | -278.21% | -59.75% | -8.07% |
| Earnings before Tax (EBT) 1 | - | -1,056 | -896.7 | -623.5 | -124.8 |
| Net income 1 | -954 | -1,053 | -894.1 | -621.5 | -124.2 |
| Net margin | - | -824.94% | -262.38% | -57.22% | -6.41% |
| EPS 2 | -2.440 | -2.640 | -2.236 | -1.556 | -0.3125 |
| Free Cash Flow 1 | - | -1,283 | -860.8 | -627.7 | 8.925 |
| FCF margin | - | -1,004.52% | -252.61% | -57.79% | 0.46% |
| FCF Conversion (EBITDA) | - | - | - | - | 10.2% |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - |
| Announcement Date | 20/02/23 | 23/02/24 | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - |
| Net Cash position | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow 1 | - | -1,283 | -861 | -628 | 8.93 |
| ROE (net income / shareholders' equity) | - | -34.5% | -53.5% | -53.7% | -14% |
| ROA (Net income/ Total Assets) | - | -23.6% | -27.5% | -19.1% | -4.1% |
| Assets 1 | - | 4,464 | 3,257 | 3,263 | 3,030 |
| Book Value Per Share 2 | - | 6.470 | 4.230 | 2.680 | 2.260 |
| Cash Flow per Share 2 | - | -1.960 | -3.060 | -0.4800 | -0.2600 |
| Capex 1 | - | 500 | 120 | 95.1 | 55.1 |
| Capex / Sales | - | 391.51% | 35.25% | 8.76% | 2.84% |
| Announcement Date | 20/02/23 | 23/02/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
33.6
CNY
Average target price
39.92
CNY
Spread / Average Target
+18.79%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +2.78% | 1.86B | |
| +9.42% | 115B | |
| +11.84% | 106B | |
| -1.05% | 21.96B | |
| -14.15% | 21.87B | |
| -5.29% | 19.21B | |
| -4.16% | 18.08B | |
| -38.29% | 17.71B | |
| +7.99% | 14.32B | |
| +36.24% | 12.42B |
- Stock Market
- Equities
- 688062 Stock
- Financials Mabwell (Shanghai) Bioscience Co., Ltd.
